Hundal Jasmin, Lopetegui-Lia Nerea, Vredenburgh James
Internal Medicine, University of Connecticut, Farmington, USA.
Hematology and Oncology, Cleveland Clinic, Cleveland, USA.
Cureus. 2022 Jun 13;14(6):e25913. doi: 10.7759/cureus.25913. eCollection 2022 Jun.
Lung cancer continues to be the leading cause of cancer-related deaths worldwide. Many studies show lung cancer is a histologically and molecularly heterogeneous group, even within the same histological subtype. are a new tool that can identify targetable genomic mutations and impact management. JAK2 p.V617F is a mutation commonly found in myeloproliferative neoplasms but rarely identified in non-small cell lung cancer (NSCLCs). The significance of Janus Kinase (JAK2) mutation in lung cancer is not clearly understood. However, it is thought that it may have a role in treating solid tumors, such as lung cancer. We present two cases of patients diagnosed with NSCLC who were discovered to have JAK2 V617F mutation on liquid biopsy.
肺癌仍然是全球癌症相关死亡的主要原因。许多研究表明，肺癌在组织学和分子水平上是一个异质性群体，即使在同一组织学亚型内也是如此。液体活检是一种能够识别可靶向基因组突变并影响治疗管理的新工具。JAK2 p.V617F是一种常见于骨髓增殖性肿瘤但在非小细胞肺癌（NSCLC）中很少发现的突变。目前尚不清楚Janus激酶（JAK2）突变在肺癌中的意义。然而，人们认为它可能在治疗实体瘤（如肺癌）中发挥作用。我们报告了两例被诊断为NSCLC的患者，他们在液体活检中被发现存在JAK2 V617F突变。
